within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB15_RopeginterferonAlfa2b;
model RopeginterferonAlfa2b 
   extends Pharmacolibrary.Drugs.ATC.L.L03AB15;

  annotation(Documentation(
    info ="<html><body><p>Ropeginterferon alfa-2b is a mono-pegylated, long-acting interferon-alpha used primarily in the treatment of polycythemia vera and other myeloproliferative neoplasms. It is currently approved for use in certain countries for treating polycythemia vera.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following subcutaneous administration in adult patients with polycythemia vera.</p><h4>References</h4><ol><li><p>Miyachi, N, et al., &amp; Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. <i>Clinical drug investigation</i> 41(4) 391–404. DOI:<a href=&quot;https://doi.org/10.1007/s40261-021-01026-5&quot;>10.1007/s40261-021-01026-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33725322/&quot;>https://pubmed.ncbi.nlm.nih.gov/33725322</a></p></li><li><p>Huang, YW, et al., &amp; Larouche, R (2022). Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. <i>British journal of clinical pharmacology</i> 88(5) 2396–2407. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15176&quot;>10.1111/bcp.15176</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34907578/&quot;>https://pubmed.ncbi.nlm.nih.gov/34907578</a></p></li><li><p>Huang, YW, et al., &amp; Wang, MX (2021). Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. <i>Advances in therapy</i> 38(9) 4756–4770. DOI:<a href=&quot;https://doi.org/10.1007/s12325-021-01863-y&quot;>10.1007/s12325-021-01863-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34328630/&quot;>https://pubmed.ncbi.nlm.nih.gov/34328630</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end RopeginterferonAlfa2b;
